Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Ratio (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Equity Ratio for 13 consecutive years, with 0.61 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 23.29% to 0.61 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.61 through Dec 2025, up 23.29% year-over-year, with the annual reading at 0.61 for FY2025, 23.29% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.61 at Theravance Biopharma, up from 0.56 in the prior quarter.
  • The five-year high for Equity Ratio was 0.73 in Q4 2022, with the low at 0.99 in Q1 2021.
  • Average Equity Ratio over 5 years is 0.14, with a median of 0.53 recorded in 2024.
  • The sharpest move saw Equity Ratio tumbled 281.39% in 2021, then soared 180.52% in 2022.
  • Over 5 years, Equity Ratio stood at 0.9 in 2021, then surged by 180.52% to 0.73 in 2022, then dropped by 23.34% to 0.56 in 2023, then fell by 11.1% to 0.5 in 2024, then grew by 23.29% to 0.61 in 2025.
  • According to Business Quant data, Equity Ratio over the past three periods came in at 0.61, 0.56, and 0.53 for Q4 2025, Q3 2025, and Q2 2025 respectively.